Annexin Pharmaceuticals AB (publ) has entered into a license agreement with Stanford University, CA, USA granting Annexin Pharmaceuticals exclusive license to patent rights related to use of Annexin A5 in treatment of cancer. The license involves a novel therapeutic concept for treating cancer by administration of the Annexin A5 protein, functionally identical to Annexin Pharmaceuticals' drug candidate ANXV. Studies have shown that Annexin A5 acts as a potent immunomodulating anti-cancer agent acting via blocking phosphatidylserine (PS) on cancer cells (US patent No 11,253,568).
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.29 SEK | -1.02% | -3.97% | +11.54% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+11.54% | 93.86L | |
+5.33% | 11TCr | |
+12.11% | 11TCr | |
-12.56% | 2.22TCr | |
-3.23% | 2.13TCr | |
-5.57% | 1.9TCr | |
-35.21% | 1.85TCr | |
-10.86% | 1.68TCr | |
+37.57% | 1.25TCr | |
-26.24% | 808.97Cr |
- Stock Market
- Equities
- ANNX Stock
- News Annexin Pharmaceuticals AB
- Annexin Signs Exclusive Licensing Deal in Cancer